Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

NCT04722666 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

199

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated by Novartis

Conditions

Major Depressive Disorder With Suicidal Ideation With Intent

Interventions

DRUG: MIJ821 Intravenous Injection
DRUG: Placebo Intravenous Injection

Sponsor

Novartis Pharmaceuticals